Next - A Phase 1b/11 adaptive clinical trial - GBM & NSCLCGiven adequate funding we should soon see an innovative new "adaptive" clinical study. The plan is to inject Rutherrin intravenously and then determine where it has localized in the patient's body. Depending on where the PS has accumulated, that area will then be irradiated to activate the Rutherrin and safely destroy the "cancer of interest", whether it be Glio Blastoma Multiforme (“GBM”), or Non-Small Cell Lung Cancer (“NSCLC”).
"Rutherrin®, if proven successful, would thus be able to “hunt” and “localize” into cancer cells and when activated by radiation “destroy” them; wherever, they may reside in the body."